This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Test
| When | Where | Title | Presenter |
|---|---|---|---|
| Apr 11, 2022 (9:00am) | CT107 | Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma | Beatriz García-Peláez, PhD |
| Apr 11, 2022 (9:00am) | CT109 | Radiomic features in tumor assessment, preliminary results from a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with anti PD1 refractory melanoma | Ángel Alberich-Bayarri, PhD |
| April 12, 2022 (10:46-11:01am) | Hall B-C, Convention Center | Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: final results of SPOTLIGHT-203 phase 2 study | Iván Márquez-Rodas MD, PhD |